• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy.

作者信息

Lomax Anna J, McQuillan Peter I A, Hall Anthony, McArthur Grant A

机构信息

Epworth Geelong Hospital, Geelong, Victoria, Australia.

Andrew Love Cancer Centre, University Hospital Geelong, Geelong, Victoria, Australia.

出版信息

Intern Med J. 2019 Aug;49(8):1051-1053. doi: 10.1111/imj.14388.

DOI:10.1111/imj.14388
PMID:31387152
Abstract
摘要

相似文献

1
Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy.单次使用帕博利珠单抗后出现急性中毒性表皮坏死松解反应，之前有头孢菌素暴露史：抗程序性死亡蛋白 1（PD-1）治疗再次挑战成功。
Intern Med J. 2019 Aug;49(8):1051-1053. doi: 10.1111/imj.14388.
2
[Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].[抗程序性死亡蛋白1治疗导致中毒性表皮坏死松解症并致死]
Ann Dermatol Venereol. 2017 Jan;144(1):65-66. doi: 10.1016/j.annder.2016.11.012. Epub 2016 Dec 20.
3
Toxic epidermal necrolysis associated with pembrolizumab.与帕博利珠单抗相关的中毒性表皮坏死松解症。
J Oncol Pharm Pract. 2020 Jul;26(5):1259-1265. doi: 10.1177/1078155219890659. Epub 2019 Dec 6.
4
Pembrolizumab induced toxic epidermal necrolysis.帕博利珠单抗诱发中毒性表皮坏死松解症。
Curr Probl Cancer. 2020 Apr;44(2):100478. doi: 10.1016/j.currproblcancer.2019.05.001. Epub 2019 May 14.
5
Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.帕博利珠单抗致转移性宫颈鳞癌患者史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症 1 例报告
Am J Dermatopathol. 2020 Apr;42(4):292-296. doi: 10.1097/DAD.0000000000001527.
6
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.重症多形红斑、史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的临床模式与病因之间的相关性：一项国际前瞻性研究的结果
Arch Dermatol. 2002 Aug;138(8):1019-24. doi: 10.1001/archderm.138.8.1019.
7
Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.在史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症中，病变表皮角质形成细胞中PD-L1的免疫组化表达增加。
Am J Dermatopathol. 2021 Apr 1;43(4):318-320. doi: 10.1097/DAD.0000000000001816.
8
Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.帕博利珠单抗相关史蒂文斯-约翰逊综合征伴原发性肝细胞癌患者的角化不良。
Australas J Dermatol. 2022 Feb;63(1):e71-e74. doi: 10.1111/ajd.13704. Epub 2021 Aug 31.
9
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.史蒂文斯-约翰逊综合征在帕博利珠单抗治疗过程后期出现。
J Oncol Pharm Pract. 2019 Sep;25(6):1520-1522. doi: 10.1177/1078155218791314. Epub 2018 Aug 7.
10
Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like".成功再次激发对表现为“中毒性表皮坏死松解症样”的帕博利珠单抗严重苔藓样药物反应。
Eur J Dermatol. 2022 Nov 1;32(6):805-807. doi: 10.1684/ejd.2022.4378.

引用本文的文献

1
Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies.免疫药物-药物相互作用影响免疫检查点抑制剂治疗的疗效和安全性。
Chem Res Toxicol. 2024 Jul 15;37(7):1086-1103. doi: 10.1021/acs.chemrestox.4c00067. Epub 2024 Jun 24.
2
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.免疫检查点抑制剂诱导的表皮坏死松解症：评估人口统计学、临床特征和罪魁祸首药物的叙述性综述。
J Dermatol. 2024 Jan;51(1):3-11. doi: 10.1111/1346-8138.17039. Epub 2023 Nov 30.
3
Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的当前药物遗传学观点
Front Pharmacol. 2021 Apr 26;12:588063. doi: 10.3389/fphar.2021.588063. eCollection 2021.
4
Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions.驱动免疫介导的迟发性药物超敏反应的基因组风险因素。
Front Genet. 2021 Apr 16;12:641905. doi: 10.3389/fgene.2021.641905. eCollection 2021.
5
The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes.皮肤免疫相关不良事件的临床和组织病理学特征及其结局
J Clin Med. 2021 Feb 12;10(4):728. doi: 10.3390/jcm10040728.